Medtronic receives FDA approval for thoracic stent graft

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has granted approval for Medtronic’s Talent thoracic stent graft, a medical device that will allow more patients to benefit from a minimally invasive treatment for certain types of aneurysms of the descending thoracic aorta.

The Talent thoracic stent graft system makes thoracic endovascular aortic repair (EVAR) accessible to an additional 25 percent of patients because it is available in a range of diameters—from 22 mm to 46 mm, according to the Minneapolis-based Medtronic.

In April, Medtronic received FDA approval for its Talent abdominal stent graft for EVAR of abdominal aortic aneurysms.